DR. REBECCA MORGAN SHAFFER M.D.
Prescription History 1609080233
Obstetrics & Gynecology - Urogynecology and Reconstructive Pelvic Surgery in Seattle, WA

NPI Status: Active since May 10, 2007

Contact Information

1536 N 115TH ST STE 320
SEATTLE, WA
ZIP 98133
Phone: (206) 668-4477

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. REBECCA MORGAN SHAFFER M.D., an active Urogynecology and Reconstructive Pelvic Surgery specialist practicing in Seattle, WA. Our medical registry currently tracks 11 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 425 documented patient claims. Among these therapy options, the most frequently utilized medication is Myrbetriq, which accounts for 127 claims alone.


Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 77
30-Day Fills 245.6
Days Supply 7,367
WA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills66.7
Peer Average Days Supply1,990
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 185.2% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,141.24 across this reporting matrix range.

Provider Avg Cost Per Claim

$118.72

State Avg Cost Per Claim

$83.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estring

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 21
30-Day Fills 63.0
Days Supply 1,890
WA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills55.1
Peer Average Days Supply1,653
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $11,642.85 across this reporting matrix range.

Provider Avg Cost Per Claim

$554.42

State Avg Cost Per Claim

$549.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Fesoterodine Fumarate Er

Generic Formulation: Fesoterodine FumarateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 17
30-Day Fills 33.3
Days Supply 982
WA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills26.6
Peer Average Days Supply735
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,662.89 across this reporting matrix range.

Provider Avg Cost Per Claim

$274.29

State Avg Cost Per Claim

$178.75

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). By relaxing the muscles in the bladder, fesoterodine improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 127
30-Day Fills 266.0
Days Supply 7,920
WA State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills55.7
Peer Average Days Supply1,601
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 252.8% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $123,308.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$970.93

State Avg Cost Per Claim

$668.63

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Nitrofurantoin Mono-Macro

Generic Formulation: Nitrofurantoin Monohyd/M-CrystSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 18
30-Day Fills 26.0
Days Supply 482
WA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills21.9
Peer Average Days Supply229
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,121.28 across this reporting matrix range.

Provider Avg Cost Per Claim

$62.29

State Avg Cost Per Claim

$25.38

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is an antibiotic used to treat bladder infections (acute cystitis). It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections. This medication should not be used in infants younger than 1 month old (see also Precautions section). This drug should not be used to treat infections outside the bladder (including kidney infections such as pyelonephritis or perinephric abscesses).

Oxybutynin Chloride Er

Generic Formulation: Oxybutynin ChlorideSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 43
30-Day Fills 85.0
Days Supply 2,550
WA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills51.7
Peer Average Days Supply1,526
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 59.3% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,905.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$44.31

State Avg Cost Per Claim

$39.97

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics. This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 23
30-Day Fills 68.0
Days Supply 2,041
WA State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills31.4
Peer Average Days Supply932
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 43.8% more claims than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,273.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$446.66

State Avg Cost Per Claim

$390.52

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Solifenacin Succinate

Generic Formulation: Solifenacin SuccinateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 23
30-Day Fills 33.0
Days Supply 934
WA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills45.0
Peer Average Days Supply1,339
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,822.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$79.22

State Avg Cost Per Claim

$66.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A quinuclidine and tetrahydroisoquinoline derivative and selective M3 MUSCARINIC ANTAGONIST. It is used as a UROLOGIC AGENT in the treatment of URINARY INCONTINENCE.

Therapeutic Applications

Solifenacin is used to treat an overactive bladder. By relaxing the muscles in the bladder, solifenacin improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

Tolterodine Tartrate Er

Generic Formulation: Tolterodine TartrateSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 20
30-Day Fills 28.0
Days Supply 840
WA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills31.1
Peer Average Days Supply910
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,471.29 across this reporting matrix range.

Provider Avg Cost Per Claim

$73.56

State Avg Cost Per Claim

$156.57

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An ANTIMUSCARINIC AGENT selective for the MUSCARINIC RECEPTORS of the BLADDER that is used in the treatment of URINARY INCONTINENCE and URINARY URGE INCONTINENCE.

Therapeutic Applications

This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, tolterodine improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. This medication belongs to the class of drugs known as antispasmodics.

Trospium Chloride

Generic Formulation: Trospium ChlorideSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 35
30-Day Fills 87.0
Days Supply 2,610
WA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills45.2
Peer Average Days Supply1,339
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 34.6% more claims than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,580.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$45.14

State Avg Cost Per Claim

$67.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, trospium improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. Trospium belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.

Trospium Chloride Er

Generic Formulation: Trospium ChlorideSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 21
30-Day Fills 35.0
Days Supply 1,050
WA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills34.1
Peer Average Days Supply1,016
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,365.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$255.48

State Avg Cost Per Claim

$149.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat an overactive bladder. By relaxing the muscles in the bladder, trospium improves your ability to control your urination. It helps to reduce leaking of urine, feelings of needing to urinate right away, and frequent trips to the bathroom. Trospium belongs to a class of drugs known as antispasmodics. It is also known as an antimuscarinic.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. REBECCA MORGAN SHAFFER M.D. provides transparency into local medical care patterns within Seattle, WA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Urogynecology and Reconstructive Pelvic Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.